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Abstract 
 
Background: Polycystic ovarian syndrome (PCOS) is a common endocrine disorder that 
affects the fertility of reproductive-aged women due to high levels of testosterone. 
Metformin is currently used to treat patients with PCOS in order to improve the 
biochemical markers of the disease. New studies show that statin medications like 
simvastatin may prove efficacious with reduction of testosterone levels, and therefore, 
possibly increase fertility. 
 
Methods: An extensive search of MEDLINE, CINAHL, Web of Science, and EBM 
Multifiles was conducted. Articles that were not written in the English language and 
duplicate articles were excluded. 
 
Results: Three studies were identified through the search of literature. The studies 
showed that simvastatin and metformin therapy do reduce testosterone levels in patients 
with PCOS. The studies used for this review were of low to very low quality. 
 
Conclusion: Based on current research, utilizing simvastatin and metformin as dual 
therapies for patients with PCOS should not be recommended. Even though there seems 
to be some significance to the therapy in decreasing testosterone levels and other 
biochemical markers of the disease, more high-quality research is necessary to determine 
the effects of simvastatin plus metformin therapy in polycystic ovarian syndrome 
patients.  
 
Keywords: simvastatin, anticholesteremic agents, hydroxymethylglutaryl-CoA reductase 
inhibitors, metformin, polycystic ovarian syndrome 
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The use of Simvastatin Plus Metformin Therapy in Patients With 
Polycystic Ovarian Syndrome 
 
BACKGROUND 
 Polycystic ovarian syndrome (PCOS) is a common gynecologic endocrine 
disorder that affects approximately 6.6% of the reproductive-aged female population.1 
This syndrome is often diagnosed using the Rotterdam criteria which state that the patient 
must have two of the following three conditions: 1) chronic oligo- or anovulation, 2) 
hyperandrogenism as signified by biochemical or clinical signs, and/or 3) polycystic 
ovaries for which there is no other diagnosis.2 Many females exhibit clinical signs of 
PCOS such as hirsutism, acne, oligomenorrhea, and infertility caused by increased levels 
of testosterone. Therefore, therapy in PCOS patients usually targets testosterone level 
decreases in order to decrease the clinical signs of the disease. 
 Traditionally, metformin has been prescribed for the treatment of PCOS in order 
to improve the patient’s hormone profile with the ultimate goal of gaining increased 
fertility. Metformin is proven to decrease testosterone levels, decrease insulin resistance, 
and reverse menstrual cycle changes independent of weight loss.3 Effecting these changes 
hopefully results in the PCOS patient gaining some degree of fertility. 
 In addition to the clinical indications, females diagnosed with PCOS can be at risk 
for other diseases including type II diabetes mellitus, cardiovascular disease, insulin 
resistance, and dyslipidemia.4-8 Therefore, polycystic ovarian syndrome patients may 
necessitate additional therapeutic interventions, such as statin medications, which are 
prescribed for patients with cardiovascular disease.  
 Statins, also known as 3-hydroxy-3-methylglutaryl coenzyme A reductase 
inhibitors (hMG-CoA reductase inhibitors), are commonly used as treatment for 
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hyperlipidemia in order to reduce the risk of cardiovascular disease. Since PCOS patients 
have an increased cardiovascular risk and incidence of dyslipidemia, they may also 
benefit from the use of statin medications such as simvastatin. The statin drugs are known 
to be efficacious in lowering cholesterol and LDLs, but they may also prove to be 
beneficial in lowering other metabolic parameters.9,10 
 Current research is studying the effects of simvastatin and atorvastatin on the 
endocrinology profile of females with PCOS.9-11 The statins have been studied singly and 
in combination with OCP. In both the single and OCP trials, the statin medications were 
shown to decreased testosterone levels, insulin resistance, and ameliorate the lipid 
profile.11 However, studies involving metformin and simvastatin are few and far between, 
but new interest in the topic seems to be emerging.  
 This review evaluates the three studies that address the validity of metformin plus 
simvastatin therapy in PCOS patients. The clinical question that guides the assessment of 
studies asks if simvastatin plus metformin therapy is more effective, in comparison to 
monotherapy with simvastatin or metformin, for reducing total testosterone in patients 
with polycystic ovarian syndrome. 
 
METHODS 
Search Strategy 
 An extensive electronic search for articles was conducted using MEDLINE 
(Ovid), CINAHL, EBM Multifiles, and Web of Science databases. The keywords 
simvastatin, anticholesteremic agents, hydroxymethylglutaryl-CoA reductase inhibitors, 
metformin, and polycystic ovarian syndrome were utilized as search terms. Duplicate 
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articles were excluded. Articles were required to be in the English language and were not 
excluded based on date of publication. The articles cited by the included studies were 
also evaluated in addition to searching reputable websites and news articles for any 
additional studies that might meet the inclusion criteria.  
Assessment of Quality 
 The studies were assessed for validity and quality using the GRADE criteria. The 
appraisal comprises evaluation of the studies’ randomization, blindness, and precision. 
Each study was categorized into high, medium, low, or very low quality of evidence as 
seen in Table I. 
 
RESULTS 
 The literature search identified thirty studies, but only three remained after 
duplicate and irrelevant articles were removed (see Table I). The studies were performed 
in Iran and Poland at universities and associated clinics. All studies were randomized 
controlled trials, but the Kazerooni et al12 study was the only study that was also double-
blinded. In the other two studies,13,14 the participants and researchers were not blinded to 
the allocation of therapy. Those two studies (Banaszewska et al (2009)13 and (2011)14) 
were performed on the same patient population with the most recent of the two studies 
being supplementary to the primary study in 2009. Banaszewska et al (2011)14 had three 
extra participants and extended follow-up for three more months. In addition, all the 
studies used sealed envelopes to allocate the treatments. The Kazerooni et al12 study 
blinded the practitioners that were giving the patients their randomly assigned medication 
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whereas Banaszewska et al (2009)13 and (2011)14 chose to give the participants the 
allocated medications unconcealed, so only the randomization was a concealed process. 
Kazerooni et al12 
 Eighty four females were identified at an infertility clinic that was associated with 
Shiraz University of Medical Sciences in Iran. Patients from 17-29 years old were 
involved. Participants in this study were randomized into therapy groups using sealed 
envelopes, and the researchers that handled the envelopes were blinded to the patient’s 
randomization. The therapy groups received either simvastatin and metformin (treatment 
group) or metformin and placebo (control group) oral pills. The patients in the study 
groups were fairly similar with respect to prognostic factors. Additionally, no patients 
were lost to follow-up during the study. The simvastatin and metformin group took 20mg 
per day of simvastatin and 500mg three times per day of metformin. In the control group, 
metformin was dosed at 500mg three times a day and delivered with a placebo pill.12  
 The authors of this study evaluated the primary outcome, testosterone levels, at 
baseline and 12 weeks later. The study showed that serum testosterone decreased by 
approximately 25.5% in the treatment group versus only 16.8% in the control group. Both 
measures were significant with P values less than or equal to 0.002.12  
 Besides testosterone levels, the Kazerooni et al12 study also measured secondary 
outcomes that were similar to those in the other two studies. Total cholesterol, LDL, 
triglycerides, and hirsutism scores were significantly lower, and HDL was higher, in the 
simvastatin plus metformin group than in the control group. In addition, the LH to FSH 
ratio was studied and was shown to be lower in the treatment group. None of the other 
secondary outcomes changed significantly.12  
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Banaszewska et al (2009)13 and (2011)14 
 Both of these randomized controlled trials looked at the same patient population. 
The study14 that was published in 2011 included three extra participants and an extended 
follow-up period. Patients were recruited at the Poznan University of Medical Sciences in 
Poznan, Poland over a 27 month period between December 2006 and March 2009. The 
2009 study13 randomized 136 females with PCOS into three different therapeutic groups 
whereas the 2011 study14 randomized 139 females into the same groups. The females 
either received oral simvastatin at a dose of 20mg once a day, oral metformin at a dose of 
850mg twice a day, or oral simvastatin plus oral metformin therapy at a dose of 20mg 
once per day and 850mg twice per day, respectively.13,14  
 The patients were randomized into the three separate study groups (simvastatin 
only, metformin only, and simvastatin plus metformin) using random number tables to set 
the blocks used to allocate patients in a 1:1:1 ratio. The randomization was concealed 
until the patient actually received the allocated medication. The patients in the study 
groups were similar in respect to some important prognostic factors such as age, BMI, 
and total testosterone. However, the patients were not similar in respect to other 
important prognostic factors such as their lipid profiles (primarily in the total cholesterol 
and triglycerides).13,14 
 The initial study13 lost twenty three subjects during the three month follow-up 
period. Also, no significant adverse events were reported by the patients. Only three 
patients in the metformin only group described minor gastrointestinal discomfort while 
taking the medication, but they did not discontinue the study.13 
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 Banaszewska et al (2009)13 measured various parameters at baseline and then 
after three months of treatment with metformin and/or simvastatin. The primary outcome 
measured was the change in total testosterone levels. As displayed in Table II, this study 
found that total testosterone levels decreased in each of the therapy groups. Testosterone 
decreased by 15.1% in the combined therapy group compared with 17.1% in the 
simvastatin group and 13.6% in the metformin group. The effects were considered 
significant due to the P values of less than 0.01. Moreover, simvastatin, when taken 
alone, was found to decrease testosterone levels more than simvastatin and metformin 
combined.13  
 Secondary outcomes of the 2009 study13 included reductions in luteinizing 
hormone (LH), follicule stimulating hormone (FSH), fasting glucose (or fasting blood 
sugars), fasting insulin, insulin sensitivity index, total cholesterol, LDL, triglycerides, 
hirsutism (measured using the Ferriman/Gallwey score), BMI, and increases in HDL. 
Table II showcases the change in biochemical markers that was measured. Of those 
measurements, only total cholesterol, LDL, and triglycerides decreased significantly in 
the simvastatin plus metformin group over either of the monotherapies.13  
 The 2011 study by Banaszewska et al (2011)14 had an additional three participants 
and the follow-up was extended to six months with continued medication use. Forty two 
subjects were lost to follow-up over the extended time period and six patients on 
metformin reported gastrointestinal side effects. However, the side effects did not affect 
the six patients’ continued participation. This study measured the same outcomes as the 
original study, but evaluated the outcomes primarily from the three to six month extended 
follow-up period. The testosterone levels kept significantly decreasing from the three 
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month follow-up mark (see Table II), but the total cholesterol and LDL did not continue 
decreasing after three months. This study also found that simvastatin alone actually 
decreased testosterone levels more than in combination with metformin.14 
 
DISCUSSION 
 This systematic review indicates a greater decrease in testosterone levels in 
patients with PCOS with the use of simvastatin and metformin over just metformin 
therapy alone. Of the secondary outcomes that were evaluated, simvastatin plus 
metformin reduced total cholesterol, LDL, and triglycerides across the studies. Other 
secondary outcomes were not significant or were not assessed in some of the reviewed 
studies.  
 The Kazerooni et al12 study does not have any major limitations to methodology 
as the study was randomized and blinded. No patients were lost to follow-up in this 
study, nor were there any considerable side effects of the medications. Additionally, there 
were no inconsistent results evident. However, because of the use of surrogate outcomes, 
there is some indirectness of evidence present. Lack of precision is also exhibited by the 
variability of testosterone measurements and biochemical markers in general. All of these 
factors were taken into consideration to rank the level of evidence of this study as low. 
 The limitations of the studies by Banaszewska et al (2009)13 and (2011)14 are lack 
of allocation concealment once patients received the medications, not having a strict 
control group with two pills given for blinding purposes, loss to follow-up that was not 
addressed, and some unequal prognostic factors between groups. Therefore, the 
studies13,14 prove to have some serious limitations to methodology. Furthermore, there 
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was strong use of surrogate outcomes as demonstrated by the lengthy list of secondary 
outcomes previously mentioned. Plus, there was a lack of precision in the results since 
not all of the P values were less than 0.05. Nonetheless, these studies13,14 were evaluated 
with the GRADE criteria15 to have a very low level of evidence.  
 Another noteworthy aspect of the Banaszewska et al (2011)14 study was that three 
people were added to the studied patient population in the most recent report of the 
results. There is no mention of three subjects being added, but the numbers in the results 
section of the 2011 study14 differ from that of the 2009 study.13 This brings up the 
question of why the authors chose to include three additional subjects and why they 
would not mention the reasons for their inclusion. In addition, there is no discussion in 
either of the published studies as to the original intention to follow-up for three or six 
months. Therefore, it is difficult to judge whether the authors published results 
prematurely or extended the study based on the preliminary results. Consequently, the 
study’s methodology is intrinsically flawed.  
 All of the studies used envelopes as a concealment method which is not very 
reliable if the envelopes are not opaque. The studies were well-focused on the efficacy of 
a combination therapy of simvastatin plus metformin, but overall, the evidence presented 
was seriously faulted which decreases the validity of the results. Due to limitations in the 
methodology, precision, and indirectness of evidence these studies are not of high enough 
quality to definitively answer the review question. The weakness of study quality 
suggests that more studies are needed to evaluate the effectiveness of simvastatin plus 
metformin therapy in patients with PCOS. However, a clinician should take the results 
into account if working with patients that may have dyslipidemia and PCOS or maybe are 
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not responding as well to standard metformin only treatment. Even though using 
simvastatin alone or with metformin would be considered off-label, the medication could 
possibly be prescribed as an adjunct treatment for PCOS. 
 It is particularly important that further studies include control groups and 
treatment groups that are blinded to the treatment allocation. Including a dose response 
gradient in further studies should also be considered as varied dosages of both 
simvastatin and metformin could possibly improve or decrease the treatment effect. Other 
patient-important outcomes, such as fertility, should also be directly addressed. 
Moreover, other statin medications like atorvastatin could be researched in conjunction 
with metformin to see if the observed effects are similar. 
 Interestingly, Banaszewska et al (2009)13 and (2011)14 also showed that 
simvastatin monotherapy may decrease serum testosterone even more than simvastatin in 
combination with metformin. Without further studies addressing the result of simvastatin 
only, the effectiveness of simvastatin in patients with PCOS cannot be determined.  
 Other aspects of statin use that were only briefly addressed in the studies are the 
adverse effects of statin medications and the fact that they are not generally used in 
pregnant patients.16 Statins are known for increasing liver enzymes and causing 
rhabdomyolysis in some users. This can be a potentially fatal side effect so statin use 
must be closely monitored. For patients with PCOS that are interested in a return to 
fertility as their primary reason for using therapeutic medications, a statin medication 
may not be the best choice due to the teratogenicity and incidence of possible side effects 
of the drug class.  
 
16 
 
CONCLUSION 
 In conclusion, simvastatin therapy for patients with PCOS appears to possibly 
result in significant decreases in testosterone levels, and therefore reduce the clinical 
signs of PCOS. However, simvastatin plus metformin therapy does not provide much, if 
any, additional reduction in metabolic parameters. More research in this area needs to be 
accomplished before simvastatin therapy becomes a widely used medication 
recommendation for patients with PCOS.  
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TABLES 
Table I: Characteristics of Studies 
Study Number of Participants Randomized Age Range Therapy Groups Randomization 
Allocation 
Concealmeant 
Similar Prognostic 
Factors Blindness 
Banaszewska et al (2009) 136 (113 after 23 lost to follow-up) not specified 
Simvastatin plus metformin, 
simvastatin only, metformin only Adequate Not Adequate Not Adequate Some 
Banaszewska et al (2011) 139 (97 after 42 lost to follow-up) not specified 
Simvastatin plus metformin, 
simvastatin only, metformin only Adequate Not Adequate Not Adequate Some 
Kazerooni et al 84 (42 in each study group) 17-29 
Simvastatin plus metformin, 
metformin plus placebo Adequate Adequate Adequate Double 
 
 
Table I Continued 
 
Study Complete Follow-up Loss to Follow-up Mean time of Follow-up 
Preciseness 
(CI, p-values) 
Other 
Considerations GRADE 
Banaszewska et al (2009) Yes Yes- 23 patients 3 months 
some p-values 
<0.05 None Very low 
Banaszewska et al (2011) Yes Yes- 42 patients 6 months 
some p-values 
<0.05 None Very low 
Kazerooni et al Yes No 3 months 
95% CI and 
some p-values 
<0.05 
None Low 
 
 
 
 
 
 
 
 
 
21 
 
Table II: Summary of Findings 
Study Group Number of Participants at End Age Range 
Total 
Testosterone 
Testosterone 
Percent Change 
LH:FSH 
ratio 
Fasting 
glucose 
Insulin 
sensitivity index 
Banaszewska et al (2009) Simvastatin plus Metformin 37 24.7 ± 0.6 -0.13 ± 0.03 -15.1% n/a 0.8 ± 2.4 0.07 ± 0.71 
Banaszewska et al (2009) Simvastatin only 40 26.1 ± 0.6 -0.14 ± 0.03 -16.3% n/a -2.2 ± 1.7 0.97 ± 0.41 
Banaszewska et al (2009) Metformin only 36 25.2 ± 0.7 -0.11 ± 0.04 -13.6% n/a -4.6 ± 2.2 0.34 ± 0.40 
Banaszewska et al (2011) Simvastatin plus Metformin 36 25.3 ± 0.6 -0.16 ± 0.03 -20.1% n/a -3.36 ± 2.12 0.31 ± 0.54 
Banaszewska et al (2011) Simvastatin only 28 26.3 ± 0.6 -0.22 ± 0.03 -25.6% n/a -2.85 ± 2.37 0.31 ± 0.55 
Banaszewska et al (2011) Metformin only 33 26.0 ± 0.6 -0.15 ± 0.04 -25.6% n/a -3.13 ± 2.05 0.34 ± 0.47 
Kazerooni et al Simvastatin plus Metformin 42 25.6 ± 4.32 -0.22 ± 0.06 n/a -0.51 ± 0.22 
-8.3 ± 
11.76 0.011 ± 0.002 
Kazerooni et al Metformin plus Placebo 42 24.9 ± 5.81 -0.14 ± 0.038 n/a 0.06 ± 0.24 
-8.66 ± 
16.3 0.009 ± 0.004 
 
 
Table II Continued 
 
Study Group Number of Participants at End 
Total 
Cholesterol LDL Triglycerides HDL Hirsutism BMI 
Banaszewska et al (2009) Simvastatin plus Metformin 37 -44 ± 6 -40 ± 4 -20 ± 6 0.2 ± 1.9 -0.16 ± 0.06 -0.55 ± 0.12 
Banaszewska et al (2009) Simvastatin only 40 -39 ± 6 -34 ± 5 -4.4 ± 4.2 -2.2 ± 1.4 -0.15 ± 0.07 -0.38 ± 0.10 
Banaszewska et al (2009) Metformin only 36 3.4 ± 4.4 2.0 ± 4.1 0.5 ± 4.6 2.4 ± 2.0 -0.35 ± 0.25 -0.67 ± 0.08 
Banaszewska et al (2011) Simvastatin plus Metformin 36 -34.5 ± 5.6 -31.8 ± 4.4 -13.4 ± 7.3 -0.79 ± 1.8 -1.0 ± 0.15 -1.35 ± 0.34 
Banaszewska et al (2011) Simvastatin only 28 -35.4 ± 6.1 -32.6 ± 5.0 -3.38 ± 4.20 -2.62 ± 2.74 -1.1 ± 0.1 -0.35 ± 0.15 
Banaszewska et al (2011) Metformin only 33 2.81 ± 4.63 2.4 ± 4.20 12.8 ± 7.5 0.55 ± 2.13 
-0.84 ± 
0.35 -0.93 ± 0.14 
Kazerooni et al Simvastatin plus Metformin 42 -64.8 ± 26.27 -24.52 ± 20.21 -34.28 ± 15.18 
6.92 ± 
7.13 -1.1 ± 1.2 -2.21 ± 1.51 
Kazerooni et al Metformin plus Placebo 42 -9.32 ± 24.23 -2.06 ± 5.36 -5.82 ± 17.68 -0.43 ± 4.74 -0.6 ± 1.9 -2.17 ± 1.02 
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